

Special Issue

Lipid Metabolism and Lipidomics in Human Diseases

Message from the Guest Editor

Lipids are essential biomolecules that play structural, energetic, and signaling roles in human physiology. Alterations in lipid metabolism are increasingly recognized as major drivers of disease processes, including atherosclerosis, diabetes, metabolic syndrome, cancer, and neurodegeneration. Recent advances in lipidomics, powered by high-resolution mass spectrometry and integrative bioinformatics, have enabled the comprehensive profiling of lipid species and their dynamic regulation. Lipidomics has become a central tool in understanding pathophysiological mechanisms, identifying novel biomarkers, and supporting therapeutic monitoring and personalized medicine approaches. This *Biomedicines* Special Issue, 'Lipid Metabolism and Lipidomics in Human Diseases', invites original research articles and reviews that explore the roles of lipid metabolism and lipidomic technologies in human health and disease. We particularly encourage submissions that integrate lipidomics with other omics approaches (metabolomics, genomics, proteomics) and highlight translational applications, from mechanistic insights to clinical utility.

Guest Editor

Dr. Ilenia Calcaterra

Dipartimento di Medicina Clinica e Chirurgia, Università degli Studi di Napoli Federico II, 80131 Naples, Italy

Deadline for manuscript submissions

closed (31 May 2026)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



mdpi.com/si/255676

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.2 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2026).